Neuralstem is a company in Bethesda that is making stem cell treatments for various diseases and also they are using a molecule to create a new way of treating depression since a lot of times the drugs on the market don’t work well.
Mr. Daly has over 25 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales, marketing and operations. Mr. Daly is Chairman and CEO of Neuralstem, Inc and emerging biotechnology company with clinical programs in the CNS space. In the past he was the President of U.S. Diabetes for the joint alliance between Bristol-Myers Squibb and AstraZeneca. During his 13-year tenure at Takeda Pharmaceuticals, he served as Executive Vice President with P&L responsibility for businesses across the U.S., Canada, and Central/South America. Earlier in his career, he served in the sales organizations at Merrell-Dow Pharmaceuticals (now part of Sanofi) and TAP Pharmaceuticals (formerly a division of Abbott Labs) in sales, marketing, operations and senior leadership positions at TAP and Takeda. Mr. Daly currently serves on the boards of Catalyst Pharmaceuticals (Nasdaq: CPRX) and Synergy Pharmaceuticals (Nasdaq: SGYP). Mr. Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University’s Kellogg School of Management.